Efficacy and safety of eslicarbazepine acetate as therapy in patients with fibromyalgia: A double-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial.

Trial Profile

Efficacy and safety of eslicarbazepine acetate as therapy in patients with fibromyalgia: A double-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Fibromyalgia
  • Focus Therapeutic Use
  • Sponsors Bial
  • Most Recent Events

    • 03 May 2014 Tolerability results from a pooled analysis of 5 trials in elderly patients who participated in non-epilepsy studies presented at the 66th Annual Meeting of the American Academy of Neurology.
    • 28 Mar 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT01820585).
    • 28 Jun 2012 Planned number of patients changed from 480 to 750 as reported by EudraCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top